LobbyingTiber Creek Group on Behalf of Takeda Pharmaceuticals America lobbying by quarter
Tiber Creek Group on Behalf of Takeda Pharmaceuticals America's latest lobbying report covers Q2 2026, at $30K. The four quarters Q4 2025–Q3 2026 total $90K. Its first report covers Q2 2025; the issues it reports most are Pharmacy and Medicare/Medicaid.
Tiber Creek Group on Behalf of Takeda Pharmaceuticals America
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $90K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q2 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q2 2025 | $30K | 1 |
| Q3 2025 | $30K | 1 |
| Q4 2025 | $30K | 1 |
| Q1 2026 | $30K | 1 |
| Q2 2026 | $30K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Pharmacy$120K · 4 reports
- Medicare and Medicaid$30K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- SENATE5 reports
Firms it paid
| Firm | ||
|---|---|---|
| B Hall Strategies | $150K | 5 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| JAMES BRYANT HALL ii | Staff Director, Senate Veterans Affairs Committee; Legislative Director, Senator Bob Graham | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/19for Q2 | B Hall Strategies | $30K |
| 04/09for Q1 | B Hall Strategies | $30K |
| 01/19for Q4 2025 | B Hall Strategies | $30K |
| 25/10/20for Q3 2025 | B Hall Strategies | $30K |
| 25/07/21for Q2 2025 | B Hall Strategies | $30K |
| 25/07/15for Q2 2025 | B Hall Strategies | Under $5,000 |